United taps Ascendis to add long-acting value to treprostinil for PAH
This article was originally published in Scrip
United Therapeutics has signed an exclusive agreement with Ascendis Pharma to develop yet another formulation of treprostinil, the active ingredient in United's Remodulin injection, a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH).
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.